舌下免疫法治疗变应性鼻炎的有效性及细胞因子对其疗效的预测

孙子慧; 高照慧; 薛金梅; 王雪松; 宋梦婷

doi:10.13201/j.issn.1001-1781.2019.04.011

舌下免疫法治疗变应性鼻炎的有效性及细胞因子对其疗效的预测

- 1 山西医科大学(太原, 030001);
- 2 山西医科大学第二医院耳鼻咽喉头颈外科;
- 3 滨州市中心医院耳鼻咽喉科
基金项目:
山西省重点研发计划项目(No:201803D31117)

山西省留学人员科技活动择优资助重点项目(No:201710)

详细信息

通讯作者: 薛金梅,E-mail:xjment@126.com

中图分类号: R765.21

收稿日期: 2018-12-03

The efficacy of sublingual immunotherapy for allergic rhinitis and the predictive role of cytokines in its therapeutic effect

- 1 Shanxi Medical University, Taiyuan, 030001, China;
- 2 Department of Otolaryngology Head and Neck Surgery, the Second Hospital of Shanxi Medical University;
- 3 Department of Otolaryngology, Binzhou Central Hospital

More Information

Corresponding author: XUE Jinmei, E-mail: xjment@126.com

Received Date: 03 December 2018

摘要

摘要: 目的:观察舌下免疫法(SLIT)治疗成人变应性鼻炎(AR)的疗效,并探讨基线血清细胞因子水平对其疗效的预测意义。方法:以屋尘螨致敏的中-重度持续性AR患者(60例)为研究对象,共治疗2年。SLIT组(30例)采用标准化尘螨疫苗SLIT及常规药物治疗,对照组(30例)采用安慰剂及常规药物治疗,比较两组基线和2年末症状药物联合评分(CSMS),评估疗效;按疗效分别将SLIT组和对照组进行组内分组比较,比较各组内有效组和无效组基线IFN-γ、IL4、IL10、IL17水平差异;绘制ROC曲线以寻找对疗效具有最佳预测意义的指标,并计算其最佳cut-off值。结果:①SLIT组与对照组的基线CSMS比较差异无统计学意义(P>0.05),2年末组间CSMS比较差异有统计学意义(P<0.05)。②SLIT组内,有效组基线IFN-γ、IL17与无效组比较均差异无统计学意义(P>0.05),基线IL4显著较高、IL10显著较低(P<0.05);对照组内,有效组基线IFN-γ、IL4、IL10、IL17与无效组比较均差异无统计学意义(P>0.05)。③基线IL4/IL10较IL4、IL10具有较高的预测价值,最佳cut-off值为2.04,敏感度为72.7%,特异度为73.7%。结论:SLIT联合常规药物较单纯药物治疗AR更有效;IL4/IL10在一定程度上能较IL4、IL10更好地预测SLIT的效果,比值越大者可能疗效越佳。
- 鼻炎 /
- 变应性 /
- 舌下免疫治疗 /
- 细胞因子 /
- 症状药物联合评分 /
- 生物标志物 /
- 受试者工作特征曲线
Abstract: Objective: The study aimed to investigate the efficacy of sublingual immunotherapy(SLIT) in treatment of adult allergic rhinitis, and to explore the predictive role of baseline serum cytokine levels in its therapeutic effect. Method: Sixty patients with moderate-severe perennial AR sensitized with house dust mites were treated for 2 years. The SLIT group(n=30) were treated with standardized dust mite vaccine SLIT and conventional drugs, and the control group(n=30) were treated with placebo and conventional drugs. The combined symptom and medication score(CSMS) were compared between the two groups to evaluate the efficacy at baseline and 2-year endpoint. According to therapeutic effect, the SLIT group and the control group were divided into subgroups respectively, and the baseline IFN-γ and IL4, IL10, IL17 levels were compared between the effective group and the ineffective group in each group. The ROC curve was drawn to find the best predictive index and the best cut-off value was calculated. Result: ①There was no significant difference between the SLIT group and the control group at baseline CSMS(P>0.05). There was significant difference between the two groups at 2-year endpoint CSMS(P<0.05). ②In the SLIT group, there was no significant difference between the effective group and the ineffective group with the IFN-γ and IL17(P>0.05). The IL4 level in the effective group was significantly higher than the ineffective group while the IL10 level was significantly lower(P<0.05). In the control group, there were no significant differences in the levels of IFN-γ, IL4, IL10 and IL17 between the two subgroups(P>0.05). ③Baseline IL4/IL10 has higher predictive value than IL4 and IL10 alone. The best cut-off value is 2.04, and the sensitivity and specificity of predictive value were 72.7% and 73.7% respectively.Conclusion: SLIT combined with conventional drug therapy is more effective than conventional drug therapy alone. IL4/IL10 has a better predictive role in SLIT effect than IL4 or IL10 alone. The higher the ratio, the better therapeutic effect is.
- rhinitis /
- allergic /
- sublingual immunotherapy /
- cytokine /
- combined symptom and medication score /
- biomakers /
- receiver operating characteristic curve

HTML全文

参考文献(18)

[1]	刘琢扶,胡娴亭,冯仙,等.变应性鼻炎及其对哮喘的影响(ARIA)2016年修订版解读[J].临床耳鼻咽喉头颈外科杂志,2017,31(17):1327-1329.
[2]	BURKS A W,CALDERON M A,CASALE T,et al.Update on allergy immunotherapy:American Academy of Allergy,Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report[J].J Allergy Clin Immunol,2013,131:1288-1296.
[3]	CANONICA G W,COX L,PAWANKAR R,et al.Sublingual immunotherapy:World Allergy Organization position paper 2013 update[J].World Allergy Organ J,2014,7:6-6.
[4]	LIN S Y,EREKOSIMA N,KIM J M,et al.Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma:a systematic review[J].JAMA,2013,309:1278-1288.
[5]	CHENG L,ZHOU W C.Sublingual immunotherapy of house dust mite respiratory allergy in China[J].Allergol Immunopathol(Madr),2019,47:85-89.
[6]	GALLI S J.Toward precision medicine and health:Opportunities and challenges in allergic diseases[J].J Allergy Clin Immunol,2016,137:1289-1300.
[7]	SINDHER S B,LONG A,ACHARYA S,et al.The use of biomarkers to predict aero-allergen and food immunotherapy responses[J].Clin Rev Allergy Immunol,2018,55:190-204.
[8]	SHAMJI M H,KAPPEN J H,AKDIS M,et al.Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma:an EAACI Position Paper[J].Allergy,2017,72:1156-1173.
[9]	PFAAR O,DEMOLY P,GERTH VAN WIJK R,et al.Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis:an EAACI Position Paper[J].Allergy,2014,69:854-867.
[10]	ZUBERBIER T,BACHERT C,BOUSQUET P J,et al.GA²LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma[J].Allergy,2010,65:1525-1530.
[11]	尤少华,秦晓燕,徐丛,等.舌下含服和皮下注射特异性免疫治疗变应性鼻炎的疗效研究[J].临床耳鼻咽喉头颈外科杂志,2016,30(9):689-693.
[12]	GU Z W,WANG Y X,CAO Z W.Neutralization of interleukin-17 suppresses allergic rhinitis symptoms by downregulating Th2 and Th17 responses and upregulating the Treg response[J].Oncotarget,2017,8:22361-22369.
[13]	DI LORENZO G,MANSUETO P,PACOR ML,et al.Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen specific immunotherapy[J].J Allergy Clin Immunol,2009,123:1103-1110.
[14]	FUJIMURA T,YONEKURA S,TANIGUCHI Y,et al.The induced regulatory T cell level,defined as the proportion of IL-10(+)Foxp3(+)cells among CD25(+)CD4(+)leukocytes,is a potential therapeutic biomarker for sublingual immunotherapy:a preliminary report[J].Int Arch Allergy Immunol,2010,153:378-387.
[15]	IHARA F,SAKURAI D,YONEKURA S,et al.Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy[J].Allergy,2018,73:1823-1832.
[16]	SCADDING G W,EIFAN A O,LAO-ARAYA M,et al.Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge[J].Allergy,2015,70:689-696.
[17]	RADULOVIC S,JACOBSON M R,DURHAM S R,et al.Grass pollen immunotherapy induces Foxp3-expressing CD4⁺ CD25⁺ cells in the nasal mucosa[J].J Allergy Clin Immunol,2008,121:1467-1472.
[18]	LOTVALL J,AKDIS C A,BACHARIER L B,et al.Asthma endotypes:a new approach to classification of disease entities within the asthma syndrome[J].J Allergy Clin Immunol,2011,127:355-360.